Viread, Tenofovir News

Our award-winning series of patient information booklets. Each title provides a comprehensive overview of one aspect of living with HIV.

Every now and then, a new HIV drug moves through the pipeline that generates a great deal of hope and encouragement.

In a new study published in The Lancet , pre-exposure prophylaxis with oral tenofovir , a commonly used antiretroviral agent, helped cut the risk of human immunodeficiency virus infection by nearly half in intravenous drug users.

The medication tenofovir, or Viread, taken once a day may prevent HIV transmission among injection drug users, U.S. researchers say.

The results from the study-the first conducted among people who inject drugs-are consistent with previous studies among men and women primarily at risk of acquiring HIV through sex.

The newer antivirals tenofovir and entecavir inhibit hepatitis B virus replication more effectively than older agents, but good adherence is needed to maintain long-term viral suppression, according to a set of studies presented at the Digestive Disease Week meeting last month in Orlando.

Continued bone loss among HIV positive men with osteopenia was modest overall, but about 25% of those taking tenofovir experienced significant loss, according to a recent study.

Investigators analysed immunological outcomes in over 72,000 people starting first-line treatment in southern Africa.